Table 2a.
Risk Estimates for the Phe31Ile SNP in Esophageal Cancer Patients Treated by Cisplatin-Based Preoperative CTXRT
| Genotypes | Clinical | Outcome | Adjusted OR* (95% CI) |
|---|---|---|---|
| <Path CR | Path CR | ||
| TT | 39 | 30 | Reference |
| AT | 43 | 15 | 2.28 1.01-5.17 |
| AA | 5 | 2 | 1.30 0.19-8.80 |
| AT + AA | 2.15 0.98-4.75 | ||
| Recurrence | No recurrence | ||
| TT | 16 | 53 | |
| AT | 29 | 29 | 3.76 1.62-8.70 |
| AA | 1 | 6 | 0.97 0.11-8.59 |
| AT + AA | 3.43 1.48-7.96 | ||
| Dead | Not dead | ||
| TT | 33 | 36 | Reference |
| AT | 38 | 20 | 1.20 0.70-2.08 |
| AA | 1 | 6 | 0.19 0.02-1.58 |
| AT + AA | 1.09 0.64-1.88 | ||
| Dead or recurrence |
Not dead or recurrence |
||
| TT | 34 | 35 | Reference |
| AT | 40 | 18 | 1.47 0.85-2.53 |
| AA | 1 | 6 | 0.20 0.03-1.61 |
| AT + AA | 1.30 0.76-2.24 |
Abbreviations: CI, confidence interval; CTXRT, chemoradiotherapy; OR, odds ratio; SNR single nucleotide polymorphism.
a
Adjusted by age, gender, tumor type, tumor location, histology, clinical stage, radiation dose, chemoradiation sequence, and chemotherapy regimens.